



Docket No. JAB-1463

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gordon et al.

Serial No.: 09/869,198

Art Unit:

Filed

: June 21, 2001

Examiner:

Int.App.No.: PCT/US99/30503

For

: Vascular Endothelial Growth Factor-X

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

November 5, 200

(Date)

Myra H. McCormack

Name of applicant, assignee, or Registered Representative

Y/5/2001

(Date of Signature)

Assistant Commissioner for Patents Washington, D.C. 20231

PRELIMINARY AMENDMENT IN RESPONSE TO THE NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

Dear Sir:

In response to the Notice to Comply with Sequence Listing Requirements mailed September 20, 2001 kindly amend the application as follows:

IN THE SPECIFICATION:

Kindly delete the sequence listing beginning at page 56 of the specification.